Fundz

Inspirna reported raising $55.1 Million in an amended SEC Form D filing, from an offering of $55.1 Million

PRIVATEAug 29, 2022

Amount Raised

$55.1 Million

$55.1 Million sold, per SEC Form D (first sale Jun 24, 2022)

Round Type

Venture

New YorkBiotechnology

Quick answer

Inspirna raised $55.1 Million in a funding round, dated June 24, 2022. Inspirna is based in New York, New York, United States.

How much did Inspirna raise?
Inspirna raised $55.1 Million in a funding round on June 24, 2022.
What does Inspirna do?
Inspirna, Inc., is a privately-held clinical stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need.
Where is Inspirna based and how big is it?
Inspirna is based in New York, New York, United States.
Who are the decision-makers at Inspirna?
Fundz holds 1 contact at Inspirna. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Inspirna that raised within 45 days of this round, from Fundz verified event records.

  • Innervace raised $10M on August 8, 2022.
  • Avinger Inc raised $2.4M (Seed) on August 8, 2022.
  • Eyestem raised an undisclosed amount (Funding Round) on August 8, 2022.
  • Nortis Inc raised $6M on August 8, 2022.
  • Skylark Bio raised $23M on August 8, 2022.
  • Epigenic Therapeutics raised $20M (Series A) on August 6, 2022.

Who to call at Inspirna, and when

A new round usually means Inspirna is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Inspirna raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Inspirna, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Inspirna. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Inspirna

Location

310 EAST 67TH STREET, SUITE 1-12

New York, New York, United States

About

Inspirna, Inc., is a privately-held clinical stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. The company is pursuing several first-in-class drug candidates. Inspirna’s lead drug candidate, ompenaclid (RGX-202), is an orally-administered small molecule that targets the CKB/SLC6A8 pathway. This pathway becomes activated in the tumors of select patients where it enables the generation of the energy molecule ATP in response to tumor hypoxia. Ompenaclid is currently being tested in multiple mid stage clinical trials in patients with advanced or metastatic RAS mutant colorectal cancer.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Inspirna raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts17 people are listed at Inspirna. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Inspirna's next move

See what Strategic adds

Inspirna raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.